CUR-001 / Currus Biologics - LARVOL DELTA

Currus Biologics…announces that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for its lead programme, CUR-001 (GlobeNewswire) - "The clearance enables Currus to initiate a first-in-human Phase 1 basket trial in patients with mesothelin-positive advanced refractory solid tumours....CUR-001 combines Currus’ BEAT (Bispecific Engagers of Antigen Presenting Cells and T cells) bispecific antibody, CURB-001 with CURT-001, a FLAG-tagged autologous CAR T-cell therapy targeting mesothelin, a protein expressed at high levels across a range of solid tumours."

First-in-human • IND • New P1 trial • Solid Tumor